In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need

Executive Summary

A newly launched grass roots campaign aimed at academics and the biotech community offers some insight into Sanofi's reinvigorated R&D organization, which is meant to be more flexible and entrepreneurial. Despite the potential upheaval caused by its recent $20.1 billion acquisition of Genzyme, Sanofi is talking up a handful of targeted areas of high unmet need and commensurately huge opportunities that are a critical part of its long-range strategy.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts